NASD · Healthcare · Biotechnology · USA
Kymera Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines using targeted protein degradation technology to address disease-causing proteins. The company has programs targeting STAT6, IRF5, and IRAK4, with clinical trials for atopic dermatitis and asthma. Kymera maintains research initiatives in other therapeutic areas and collaborations with pharmaceutical partners.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kymera Therapeutics Inc stock.
Overvalued: intrinsic value $8.52 per share, market price $113.46, margin of safety -1232.4% (as of 2026-10-20).
Its liquidation floor, current assets minus every liability, values the shares at $8.52; the price of $113.46 is 1232% above that value.
17 more funds hold it; the full list is part of the paid plan.
122 more in this industry show a wider margin of safety.
KYMR is overvalued (as of the 2026-10-20 close). Its liquidation floor, current assets minus every liability, values the shares at $8.52; the price of $113.46 is 1232% above that value.
$8.52 per share (as of the 2026-10-20 close), against a market price of $113.46. That is a margin of safety of -1232.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.